Madeleine delivers strategic, data-driven recommendations to leading pharmaceutical and biotechnology clients across a wide range of therapeutic areas including oncology, CNS disorders, cardiovascular disease, infectious disease, immunology, and rare disease.
Her business engagements have been expansive, including commercial opportunity assessments, pricing and market access strategy, launch strategy, demand forecasting, and navigation of changes due to the Inflation Reduction Act.
Prior to joining Putnam in 2020, Madeleine worked in Operations at a health insurance tech start-up. She earned her BA in Biology & Society with a minor in Applied Economics and Management from Cornell University in 2018.